Erythropoietin polysialic (Xenetic Biosciences)

N/A

Report date: 2024/12/18 11:45:16

Base Information

Drug NameErythropoietin polysialic (Xenetic Biosciences)
Drug Alias NamePolysialic erythropoietinPolysialic EPOErepoXenErepoXenEpolong +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLipoxen Technologies LtdSerum Institute Of India Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLipoxen Technologies LtdSynbioXenetic Biosciences Inc +[4] 
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A